Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)

Status Not yet recruiting

Clinical Trial Summary

There are currently no target therapies approved for treatment of anaplastic thyroid cancer (ATC), leading to a clear need for improving therapy for ATC. This is a single-arm, multicenter study to evaluate the efficacy and safety of HX008 injection in patients with metastatic or locally advanced anaplastic thyroid cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04574817
Study type	Interventional
Source	Taizhou Hanzhong biomedical co. LTD
Contact	Yuankai Shi
Phone	010-87788293
Email	syuankai@cicams.ac.cn
Status	Not yet recruiting
Phase	Phase 2
Start date	December 28, 2020
Completion date	May 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04420754` - Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer	Phase 1
Completed	`NCT02152137` - Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer	Phase 2
Active, not recruiting	`NCT04552769` - Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer	Phase 2
Active, not recruiting	`NCT04400474` - Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study	Phase 2
Completed	`NCT02688608` - Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer	Phase 2
Terminated	`NCT00095693` - Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer	Phase 2
Active, not recruiting	`NCT01240590` - A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)	Phase 1/Phase 2
Not yet recruiting	`NCT05819593` - Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences
Active, not recruiting	`NCT04579757` - Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT06362694` - Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy	Phase 2
Recruiting	`NCT06374602` - Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer	Phase 2
Withdrawn	`NCT01701349` - Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer	Phase 3
Active, not recruiting	`NCT03085056` - Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer	Early Phase 1
Recruiting	`NCT01774279` - interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT)
Terminated	`NCT00126568` - Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer	Phase 2
Completed	`NCT02244463` - A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT05696548` - Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)	Phase 2
Terminated	`NCT00603941` - A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel	Phase 1/Phase 2
Completed	`NCT00280852` - Review of Multimodality Management of Anaplastic Thyroid Cancer	N/A
Recruiting	`NCT04238624` - Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer	Phase 2